Proteome Sciences appoints CEO

18 May 2016

UK-based Proteome Sciences (LSE: PRM) has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval).

The appointment comes against the buoyant background and trajectory of the PS Biomarker Services business, and Proteome says it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of executive chairman.

Mr Haigh is a strong advocate of precision medicine and will bring numerous industry contacts and considerable commercial experience to the role. He is an established leader in the biopharmaceutical sector with 30 years in clinical and operational research and development, principally at Merck and Amgen where most recently he was European chief operating officer, R&D.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK